| Literature DB >> 30846834 |
Megan S Grace1, Melissa F Formosa1, Kiymet Bozaoglu1,2, Audrey Bergouignan3,4,5, Marta Brozynska1,6, Andrew L Carey1, Camilla Bertuzzo Veiga1, Parneet Sethi1, Francis Dillon1, David A Bertovic1, Michael Inouye1,6, Neville Owen1,7, David W Dunstan1,8, Bronwyn A Kingwell9.
Abstract
Active breaks in prolonged sitting has beneficial impacts on cardiometabolic risk biomarkers. The molecular mechanisms include regulation of skeletal muscle gene and protein expression controlling metabolic, inflammatory and cell development pathways. An active communication network exists between adipose and muscle tissue, but the effect of active breaks in prolonged sitting on adipose tissue have not been investigated. This study characterized the acute transcriptional events induced in adipose tissue by regular active breaks during prolonged sitting. We studied 8 overweight/obese adults participating in an acute randomized three-intervention crossover trial. Interventions were performed in the postprandial state and included: (i) prolonged uninterrupted sitting; or prolonged sitting interrupted with 2-minute bouts of (ii) light- or (iii) moderate-intensity treadmill walking every 20 minutes. Subcutaneous adipose tissue biopsies were obtained after each condition. Microarrays identified 36 differentially expressed genes between the three conditions (fold change ≥0.5 in either direction; p < 0.05). Pathway analysis indicated that breaking up of prolonged sitting led to differential regulation of adipose tissue metabolic networks and inflammatory pathways, increased insulin signaling, modulation of adipocyte cell cycle, and facilitated cross-talk between adipose tissue and other organs. This study provides preliminary insight into the adipose tissue regulatory systems that may contribute to the physiological effects of interrupting prolonged sitting.Entities:
Mesh:
Year: 2019 PMID: 30846834 PMCID: PMC6405989 DOI: 10.1038/s41598-019-40490-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study design and protocol.
Genes differentially expressed between the three experimental conditions.
| Gene Symbol | Overall condition | Light vs Sit | Mod vs Sit | Mod vs Light | Definition | |||
|---|---|---|---|---|---|---|---|---|
| P Value | Fold Change | P Value | Fold Change | P Value | Fold Change | P Value | ||
| APBB3 | 0.037 | 0.62 | 0.001 | 1.08 | 0.92 | Amyloid beta precursor protein binding family member 3 | ||
| CLDN15 | 0.044 | 0.59 | 0.0006 | 1.01 | 1.00 | Claudin 15 | ||
| CLEC4GP1 | 0.033 | 0.72 | 0.004 | 1.11 | 0.67 | < | C-type lectin domain family 4 member G pseudogene 1 | |
| CLK2 | 0.0008 | 0.68 | <0.0001 | 1.07 | 0.84 | < | CDC like kinase 2 | |
| CPLX1 | 0.030 | 0.90 | 0.91 | Complexin 1 | ||||
| GDPD3 | 0.006 | 0.57 | <0.0001 | 0.95 | 0.97 | Glycerophosphodiester phosphodiesterase domain containing 3 | ||
| HUWE1 | 0.001 | 0.67 | <0.0001 | 1.07 | 0.84 | < | HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase | |
| ID1 | 0.004 | 0.62 | <0.0001 | 0.99 | 1.00 | < | Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein | |
| KIAA0922 | 0.011 | 0.66 | <0.0001 | 0.99 | 1.00 | Transmembrane 131 like | ||
| LOC100133930 | 0.0005 | 0.58 | <0.0001 | 0.92 | 0.84 | < | Similar to D-2-hydroxyglutarate dehydrogenase | |
| LOC653658 | 0.006 | < | 1.27 | 0.092 | 0.73 | 0.016 | Ribosomal protein S23 pseudogene 8 | |
| LOC728590 | 0.030 | < | 1.47 | 0.002 | 0.92 | 0.86 | Ribosomal protein S27a pseudogene 11 | |
| LOC729200 | 0.006 | < | 1.13 | 0.56 | 0.70 | 0.001 | Small nuclear ribonucleoprotein polypeptide B2 pseudogene | |
| LTB4R | 0.030 | 0.69 | 0.001 | 1.06 | 0.92 | Leukotriene B4 receptor | ||
| LUC7L | 0.032 | 0.64 | 0.0003 | 0.99 | 1.00 | Luciferase 7 like | ||
| MAN2C1 | 0.008 | 0.59 | <0.0001 | 1.01 | 1.00 | < | Mannosidase alpha class 2C member 1 | |
| MCF2L | 0.008 | 0.54 | <0.0001 | 0.89 | 0.78 | MCF2 transforming sequence-like protein | ||
| MSH5 | 0.001 | 0.71 | 0.0002 | 1.09 | 0.68 | < | MutS homolog 5 | |
| MTCP1 | 0.027 | < | 1.20 | 0.38 | 0.69 | 0.008 | Mature T-cell proliferation 1 | |
| MYO1C | 0.0003 | 0.64 | <0.0001 | 0.98 | 1.00 | < | Myosin 1c | |
| NOS3 | 0.013 | 0.51 | <0.0001 | 0.88 | 0.80 | Nitric oxide synthase 3 | ||
| PDGFB | 0.015 | 0.62 | <0.0001 | 0.95 | 0.94 | Platelet derived growth factor subunit b | ||
| PFKFB3 | 0.029 | 0.81 | 0.42 | < | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | |||
| PKD1 | 0.0003 | 0.60 | <0.0001 | 0.95 | 0.94 | < | Polycystin 1, transient receptor potential channel interacting | |
| PKD1L2 | 0.0005 | 0.56 | <0.0001 | 1.00 | 1.00 | < | Polycystin 1 like 2 | |
| PSMA3 | 0.0002 | < | 0.99 | 1.00 | 0.64 | <0.0001 | Proteasome subunit alpha 3 | |
| RGS11 | 0.045 | 0.54 | 0.0004 | 0.98 | 1.00 | Regulator of g protein signalling 11 | ||
| RPL9 | 0.008 | < | 1.35 | 0.30 | 0.55 | 0.004 | Ribosomal protein L9 | |
| SAFB | 0.023 | 0.60 | 0.0002 | 1.00 | 1.00 | Scaffold attachment factor b | ||
| SPG7 | 0.040 | 0.68 | 0.002 | 1.07 | 0.92 | Spastic paraplegia 7, paralegin matrix AAA peptidase subunit | ||
| STAT1 | 0.010 | < | 1.16 | 0.36 | 0.73 | 0.004 | Signal transducer and activator of transcription 1 | |
| TIE1 | 0.001 | < | 0.84 | 0.53 | Tyrosine kinase with immunoglobulin like and EGF like domains 1 | |||
| TNFRSF25 | 0.0005 | 0.56 | <0.0001 | 1.10 | 0.83 | < | Tumour necrosis factor receptor superfamily member 25 | |
| ZBTB46 | 0.047 | 0.54 | <0.0001 | 0.82 | 0.46 | Zinc finger and BTB domain containing 46 | ||
| ZNF767 | 0.030 | 0.70 | 0.002 | 1.10 | 0.75 | 1.57 | <0.0001 | Zinc finger family member 767, pseudogene |
| ZXDC | 0.0008 | 0.64 | <0.0001 | 1.02 | 1.00 | < | ZXD family zinc finger C | |
Overall condition P value indicates the corrected false discovery rate P value for the post-hoc Wald test. Pairwise condition comparison P values are corrected by the Dunn-Sidak approach. Comparisons meeting the 0.5 fold change criteria (in either direction) and meeting the significance threshold are highlighted in bold: fold change comparisons < 1 indicate downregulation, and >1 upregulation of the gene relative to the comparison condition. Light vs Sit = light intensity breaks versus uninterrupted sitting; Mod vs Sit = moderate intensity breaks versus uninterrupted sitting; Mod vs Light = moderate intensity breaks versus light intensity breaks.
Figure 2Genes differentially expressed between the three experimental conditions. Heat map showing those genes up (blue) and down (green) regulated for comparisons of Light vs Sit (light intensity breaks versus uninterrupted sitting, column 1); Mod vs Sit (moderate intensity breaks versus uninterrupted sitting, column 2) and Mod vs Light (moderate intensity breaks versus light intensity breaks, column 3). Comparisons meeting both the 0.5 fold change criteria (in either direction from 1) and the significance threshold are highlighted in Table 1. Refer to Table 1 for gene definitions.
Figure 3Pathways differentially regulated between the three experimental conditions. Heat map showing pathways up (blue, Normalized Enrichment Score (NES) >0) and down (green, NES <0) regulated for comparisons of Light vs Sit (light intensity breaks versus uninterrupted sitting, column 1); Mod vs Sit (moderate intensity breaks versus uninterrupted sitting, column 2) and Mod vs Light (moderate intensity breaks versus light intensity breaks, column 3). The significance of these comparisons are indicated in Supplementary Table 1. ATP = adenosine triphosphate; BCR = B cell receptor; ER = endoplasmic reticulum; MHC = major histocompatibility; Resp. electr. transp = respiratory electron transport; TCA = tricarboxcylic acid.